Jpmorgan Chase & CO Viracta Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 721 shares of VIRX stock, worth $180. This represents 0.0% of its overall portfolio holdings.
Number of Shares
721
Previous 721
-0.0%
Holding current value
$180
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding VIRX
# of Institutions
41Shares Held
5.63MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.52MShares$380,0600.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA954KShares$238,6210.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA690KShares$172,4270.09% of portfolio
-
Stonepine Capital Management, LLC Bend, OR500KShares$125,0000.07% of portfolio
-
Laurion Capital Management LP New York, NY332KShares$83,0470.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $9.39M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...